📊 ACIU Key Takeaways
Is AC Immune SA (ACIU) a Good Investment?
Unable to assess AC Immune SA fundamentals due to insufficient financial data. With only 1 metric available and no income statement, balance sheet, or cash flow information, a meaningful analysis of profitability, financial health, or growth quality cannot be conducted. Data quality is critically inadequate for investment assessment.
AC Immune's fundamentals remain weak: 2025 revenue fell sharply to CHF 3.6 million from CHF 27.3 million, operating loss widened to CHF 69.3 million, and operating cash flow turned to a CHF 69.3 million outflow. The balance sheet still provides a cushion with CHF 91.4 million of cash and short-term financial assets and management says funding extends to the end of Q3 2027, but the business remains dependent on milestone-based collaboration revenue rather than durable product sales or self-sustaining profitability.
Why Buy AC Immune SA Stock? ACIU Key Strengths
- No strengths identified
- Cash and short-term financial assets totaled CHF 91.4 million at December 31, 2025, supporting operations into Q3 2027 per management
- R&D expense declined to CHF 56.4 million from CHF 62.6 million and G&A fell to CHF 16.1 million, showing some cost discipline after restructuring
- The company has meaningful collaboration support, including large deferred contract revenue balances that can convert into recognized revenue over time
ACIU Stock Risks: AC Immune SA Investment Risks
- Extreme data scarcity prevents fundamental analysis
- No revenue, profitability, or cash flow visibility
- No balance sheet data to assess financial stability
- No insider trading activity to gauge management confidence
- Insufficient metrics available (1 out of required 20+) for comprehensive evaluation
- There is still no product-sale revenue, and 2025 total revenue dropped to CHF 3.6 million from CHF 27.3 million, highlighting very low revenue quality and high lumpiness
- Net loss widened to CHF 70.4 million and operating cash flow swung from a 2024 inflow to a CHF 69.3 million outflow in 2025
- Equity fell to CHF 44.9 million from CHF 112.3 million and liquidity is tighter, with current assets only modestly above current liabilities
Key Metrics to Watch
- Revenue and net income trends when available
- Cash position and burn rate for pre-revenue pharmaceutical development
- Clinical trial progress and pipeline advancement
- Operating cash flow and runway sustainability
- Cash plus short-term financial assets relative to annual operating cash burn
- Contract revenue and milestone/deferred revenue conversion from partner agreements
AC Immune SA (ACIU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ACIU Profit Margin, ROE & Profitability Analysis
ACIU vs Healthcare Sector: How AC Immune SA Compares
How AC Immune SA compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AC Immune SA Stock Overvalued? ACIU Valuation Analysis 2026
Based on fundamental analysis, AC Immune SA has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AC Immune SA Balance Sheet: ACIU Debt, Cash & Liquidity
ACIU Revenue Growth, EPS Growth & YoY Performance
ACIU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AC Immune SA (CIK: 0001651625)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACIU
What is the AI rating for ACIU?
AC Immune SA (ACIU) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 45% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACIU's key strengths?
Claude: . ChatGPT: Cash and short-term financial assets totaled CHF 91.4 million at December 31, 2025, supporting operations into Q3 2027 per management. R&D expense declined to CHF 56.4 million from CHF 62.6 million and G&A fell to CHF 16.1 million, showing some cost discipline after restructuring.
What are the risks of investing in ACIU?
Claude: Extreme data scarcity prevents fundamental analysis. No revenue, profitability, or cash flow visibility. ChatGPT: There is still no product-sale revenue, and 2025 total revenue dropped to CHF 3.6 million from CHF 27.3 million, highlighting very low revenue quality and high lumpiness. Net loss widened to CHF 70.4 million and operating cash flow swung from a 2024 inflow to a CHF 69.3 million outflow in 2025.
What is ACIU's revenue and growth?
AC Immune SA reported revenue of N/A.
Does ACIU pay dividends?
AC Immune SA does not currently pay dividends.
Where can I find ACIU SEC filings?
Official SEC filings for AC Immune SA (CIK: 0001651625) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACIU's EPS?
AC Immune SA has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACIU a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, AC Immune SA has a SELL rating with 45% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACIU stock overvalued or undervalued?
Valuation metrics for ACIU: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACIU stock in 2026?
Our dual AI analysis gives AC Immune SA a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACIU's free cash flow?
AC Immune SA's operating cash flow is N/A, with capital expenditures of N/A.
How does ACIU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).